Why participate?
Understand the mechanisms of immunogenicity and its implications in development, regulatory affairs, and clinical outcomes.
Training Context:
The immunogenicity of therapeutic proteins is a critical issue in biopharmaceutical development, as it affects both efficacy and safety. Understanding how these proteins trigger immune responses helps design safer and more effective treatments. Evaluating immunogenicity risk is essential to meet quality and regulatory requirements, optimize clinical outcomes, and minimize risks for patients.
Interactive Teaching, Case Studies, Experience Sharing
Anyone involved in the development of biopharmaceuticals—researchers, engineers, technicians, project managers, CSOs.
Knowledge in biotechnology, biochemistry, or immunology, and in the development of biologics—or having completed the “Fundamentals of therapeutic antibodies” course.
Prices: Excluding tax, as the training is not subject to VAT.
In-house training rate: Please contact us.
Participant satisfaction rate :
Return rate of satisfaction questionnaires :
Registering online or by e-mail is a pre-registration. We will process your request within one week:
Signing the training agreement commits the company or individual to the training course. Cancellation conditions are specified in the training agreement.
When no session date is specified, pre-registration allows us to note your interest in a programme, and we will keep you informed as soon as a new session is organised.
For more information, contact Daphné Brisard: 02 47 36 63 18 or formation@mabdesign.fr
